Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease

Transplant Infectious Disease

Volumn 15, Issue 4, 2013, Pages 354-360

  Katragadda, L ^a   Shahid, Z ^a   Restrepo, A ^a   Muzaffar, J ^a   Alapat, D ^b   Anaissie, E ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Intravenous immunoglobulin; Pancytopenia; Parvovirus B19; Polymerase chain reaction; Preemptive therapy; Thrombocytopenia

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN; IMMUNOGLOBULIN; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

ADULT; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CYTOPENIA; DIAGNOSIS; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN PARVOVIRUS B19; HUMAN PARVOVIRUS B19 INFECTION; LEUKOCYTE COUNT; MALE; MEDICAL RECORD REVIEW; MULTIPLE MYELOMA; PANCYTOPENIA; PARVOVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84880797525     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12067     Document Type: Article

References (43)

1. Hsu TC, Tsay GJ. Human parvovirus B19 infection in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40 (2): 152-157.
2. Naides SJ. Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin North Am 1998; 24 (2): 375-401.
3. Enders G, Dotsch J, Bauer J, et al. Life-threatening parvovirus B19-associated myocarditis and cardiac transplantation as possible therapy: two case reports. Clin Infect Dis 1998; 26 (2): 355-358.
4. Papadogiannakis N, Tolfvenstam T, Fischler B, Norbeck O, Broliden K. Active, fulminant, lethal myocarditis associated with parvovirus B19 infection in an infant. Clin Infect Dis 2002; 35 (9): 1027-1031.
5. Hillingso JG, Jensen IP, Tom-Petersen L. Parvovirus B19 and acute hepatitis in adults. Lancet 1998; 351 (9107): 955-956.
6. Barah F, Vallely PJ, Chiswick ML, Cleator GM, Kerr JR. Association of human parvovirus B19 infection with acute meningoencephalitis. Lancet 2001; 358 (9283): 729-730.
7. Kerr JR, Barah F, Chiswick ML, et al. Evidence for the role of demyelination, HLA-DR alleles, and cytokines in the pathogenesis of parvovirus B19 meningoencephalitis and its sequelae. J Neurol Neurosurg Psychiatry 2002; 73 (6): 739-746.
8. Ardalan MR, Shoja MM, Tubbs RS, Esmaili H, Keyvani H. Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus b19 infection. Am J Transplant 2008; 8 (6): 1340-1344.
9. Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. J Intern Med 2006; 260 (4): 285-304.
10. Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R, Puccetti A. Human parvovirus B19 infection and autoimmunity. Autoimmun Rev 2008; 8 (2): 116-120.
11. Tzang BS, Tsai CC, Chiu CC, Shi JY, Hsu TC. Up-regulation of adhesion molecule expression and induction of TNF-alpha on vascular endothelial cells by antibody against human parvovirus B19 VP1 unique region protein. Clin Chim Acta 2008; 395 (1-2): 77-83.
12. Hayes-Lattin B, Seipel TJ, Gatter K, Heinrich MC, Maziarz RT. Pure red cell aplasia associated with parvovirus B19 infection occurring late after allogeneic bone marrow transplantation. Am J Hematol 2004; 75 (3): 142-145.
13. Itala M, Kotilainen P, Nikkari S, Remes K, Nikoskelainen J. Pure red cell aplasia caused by B19 parvovirus infection after autologous blood stem cell transplantation in a patient with chronic lymphocytic leukemia. Leukemia 1997; 11 (1): 171.
14. Koduri PR, Kumapley R, Valladares J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin-a report of eight patients. Am J Hematol 1999; 61 (1): 16-20.
15. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989; 321 (8): 519-523.
16. Smith MA, Shah NR, Lobel JS, Cera PJ, Gary GW, Anderson LJ. Severe anemia caused by human parvovirus in a leukemia patient on maintenance chemotherapy. Clin Pediatr (Phila) 1988; 27 (8): 383-386.
17. Lackner H, Sovinz P, Benesch M, et al. The spectrum of parvovirus B19 infection in a pediatric hemato-oncologic ward. Pediatr Infect Dis J 2011; 30 (5): 440-442.
18. Solano C, Juan O, Gimeno C, Garcia-Conde J. Engraftment failure associated with peripheral blood stem cell transplantation after B19 parvovirus infection. Blood 1996; 88 (4): 1515-1517.
19. Carstensen H, Ornvold K, Cohen BJ. Human parvovirus B19 infection associated with prolonged erythroblastopenia in a leukemic child. Pediatr Infect Dis J 1989; 8 (1): 56.
20. De Renzo A, Azzi A, Zakrzewska K, Cicoira L, Notaro R, Rotoli B. Cytopenia caused by parvovirus in an adult ALL patient. Haematologica 1994; 79 (3): 259-261.
21. Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 2006; 43 (1): 40-48.
22. Manaresi E, Gallinella G, Zuffi E, Bonvicini F, Zerbini M, Musiani M. Diagnosis and quantitative evaluation of parvovirus B19 infections by real-time PCR in the clinical laboratory. J Med Virol 2002; 67 (2): 275-281.
23. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29 (9): e45.
24. Tang JW, Lau JS, Wong SY, et al. Dose-by-dose virological and hematological responses to intravenous immunoglobulin in an immunocompromised patient with persistent parvovirus B19 infection. J Med Virol 2007; 79 (9): 1401-1405.
25. Beske F, Modrow S, Sorensen J, et al. Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40 (1): 89-91.
26. Muetherig A, Christopeit M, Muller LP, et al. Human parvovirus B19 infection with GvHD-like erythema in two allogeneic stem cell transplant recipients. Bone Marrow Transplant 2007; 39 (5): 315-316.
27. Arnold DM, Neame PB, Meyer RM, et al. Autologous peripheral blood progenitor cells are a potential source of parvovirus B19 infection. Transfusion 2005; 45 (3): 394-398.
28. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994; 330 (17): 1192-1196.
29. Corcoran A, Doyle S. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19. J Med Microbiol 2004; 6: 459-475.
30. Ozawa K, Ayub J, Kajigaya S, Shimada T, Young N. The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 1988; 62 (8): 2884-2889.
31. Pallier C, Greco A, Le Junter J, Saib A, Vassias I, Morinet F. The 3′ untranslated region of the B19 parvovirus capsid protein mRNAs inhibits its own mRNA translation in nonpermissive cells. J Virol 1997; 71 (12): 9482-9489.
32. Ozkurt ZN, Yegin ZA, Suyani E, et al. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. J Clin Apher 2010; 25 (5): 280-286.
33. Nieboer P, de Vries EG, Vellenga E, et al. Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem cell transplantation for haematological malignancies; 1-year analysis. Eur J Cancer 2004; 40 (8): 1199-1207.
34. Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med 2007; 48 (11): 1767-1776.
35. Israel VK, Jiang C, Muggia FM, et al. Intraperitoneal 5-fluoro-2′-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity study. Cancer Chemother Pharmacol 1995; 37 (1-2): 32-38.
36. Liang TB, Li DL, Yu J, et al. Pure red cell aplasia due to parvovirus B19 infection after liver transplantation: a case report and review of the literature. World J Gastroenterol 2007; 13 (13): 2007-2010.
37. Isobe Y, Sugimoto K, Shiraki Y, Nishitani M, Koike K, Oshimi K. Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy. Am J Hematol 2004; 77 (4): 370-373.
38. Egbuna O, Zand MS, Arbini A, Menegus M, Taylor J. A cluster of parvovirus B19 infections in renal transplant recipients: a prospective case series and review of the literature. Am J Transplant 2006; 6 (1): 225-231.
39. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol 2011; 11 (6): 532-538.
40. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009; 49 (8): 1211-1225.
41. Scheinfeld N. A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine. J Drugs Dermatol 2007; 6 (3): 352-355.
42. Veeraputhiran M, Sanath Kumar N, Haider S, Barlogie B, Van Rhee F, Anaissie E. The role of plasma cytokines in the diagnosis of autoimmune phenomena in patients with multiple myeloma undergoing novel anti-myeloma therapies and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17 (2 Suppl) S347-S348.
43. Boruchoff SE, Woda BA, Pihan GA, Durbin WA, Burstein D, Blacklow NR. Parvovirus B19-associated hemophagocytic syndrome. Arch Intern Med 1990; 150 (4): 897-899.